Exhibit 99.1 Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities RUTHERFORD, N.J., and LA JOLLA, CA: Sept. 23, 2026 - Lōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated therapeutic assets. A Clear View of Who We Are A Message From Our CEO, Erik Emerson Good morning. I’m Erik Emerson, CEO of Lōkahi Therapeutics™ and Glucotrack. As many of you know, we completed our strategic business combination on July 14. Since then, we have continued to work through the post-closing matters contemplated by the transaction, including the steps required for the conversion of the Series A convertible preferred stock, which remains subject to applicable Nasdaq requirements and other conditions. I wanted to take this opportunity to provide an update on where we are today, what we are building, and where we are headed next. Over the past year, Lōkahi Therapeutics™ has sharpened its focus around a clear objective: To build a clinical-stage biophar…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
GlucoTrack, Inc.
GCTKNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On September 23, 2026, Glucotrack, Inc., a Delaware corporation (the “Company”), issued a shareholder update. The update is furnished as Exhibit 99.1.…
Company context
The Company was incorporated on May 18, 2010 under the laws of the State of Delaware. We are a medical device company focused on the development of an implantable continuous blood glucose monitor (“CBGM”) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes (the “Glucotrack CBGM”).
Current securities
Historical securities (1)
Recent company filings
- 425 filingSep 23, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 18, 2026
- S-1 filingSep 18, 2026
- Entry into a Material Definitive Agreement · Submission of Matters to a Vote of Security HoldersSep 14, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD DisclosureSep 11, 2026
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01. Regulation FD Disclosure.
On
September 23, 2026, Glucotrack, Inc., a Delaware corporation (the “Company”), issued a shareholder update. The update is
furnished as Exhibit 99.1.
The
information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the
Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates
it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.